OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results

Core Insights - OptimizeRx Corp. reported strong financial results for Q4 2025, with revenue of $32.2 million and adjusted EBITDA of $12.0 million, exceeding both consensus and internal expectations [3] - For the full year 2025, the company achieved record revenue of $109.4 million, a 19% increase from $92.1 million in 2024, and adjusted EBITDA of $24.3 million, reflecting a margin of over 20% [3][7] - The company aims to maintain its status as a "Rule of 40" company, indicating a focus on sustainable growth and profitability [3] Financial Performance - Q4 2025 revenue was $32.2 million, consistent with Q4 2024's $32.3 million [6][7] - Q4 gross profit increased by 9% year-over-year to $24.1 million [6][7] - Q4 net income reached $5.0 million, compared to a net loss of $(0.1) million in Q4 2024 [7] - Full year 2025 net income totaled $5.1 million, a significant recovery from a net loss of $(20.1) million in 2024 [7] - Cash and cash equivalents increased to $23.4 million as of December 31, 2025, up from $13.4 million a year earlier [7] Guidance and Outlook - The company updated its 2026 revenue guidance to between $109 million and $114 million, with adjusted EBITDA expected to be between $21 million and $25 million [6][9] - Despite increased market volatility and customer caution regarding discretionary spending, the company remains confident in underlying demand trends [4][5] Share Repurchase Program - OptimizeRx's board authorized a share repurchase program for up to $10 million of the company's outstanding common stock, effective March 12, 2026 [10] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturers was $2,838, down from $2,976 in 2024 [8] - Net revenue retention was 116%, slightly down from 121% in 2024 [8] - Revenue per average full-time employee increased to $839 from $701 in 2024 [8]